This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
by Sundeep Ganoria
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $46.78, marking a +2.7% move from the previous day.
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
by Sundeep Ganoria
CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $44.43, representing a +2.87% change from its previous close.
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
by Ekta Bagri
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
by Sundeep Ganoria
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $42.94, representing a +2.02% change from its previous close.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
by Zacks Equity Research
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
by Zacks Equity Research
Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
by Sundeep Ganoria
CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Top Genomics Stocks to Add to Your Portfolio in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
by Zacks Equity Research
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
by Zacks Equity Research
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates. Stock tanks 12%.
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations
by Zacks Equity Research
Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -24.41% and 83.48%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
by Zacks Equity Research
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.25, moving +1.38% from the previous trading session.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).